Euthymics Bioscience Receives $24,000,000 Series A Funding

  • Feed Type
  • Date
    7/22/2010
  • Company Name
    Euthymics Bioscience
  • Mailing Address
    35 Braintree Hill Office Park Braintree, MA 02184
  • Company Description
    Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment.
  • Website
    http://www.Euthymics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $24,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The initial Series A proceeds were used to complete the acquisition of DOV Pharmaceutical, Inc. and allow for the continued development of DOV’s unique antidepressant, EB-1010 (formerly known as DOV 21,947), for patients who do not respond adequately to selective serotonin reuptake inhibitors, or SSRIs.
  • M&A Terms
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Venture Investors
  • Venture Investor
    Hambrecht & Quist Capital Management
  • Venture Investor
    GBS Venture Partners

By posting a comment, you agree to our terms and conditions.